Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) is a multinational, randomized, controlled trial designed to compare the effects of prandial versus fasting glycemic control on risk for cardiovascular outcomes in patients with type 2 diabetes after acute myocardial infarction (AMI). RESEARCH DESIGN AND METHODS—Patients (type 2 diabetes, aged 30–75 years) were randomly assigned within 21 days after AMI to the 1) prandial strategy (PRANDIAL) (three premeal doses of insulin lispro targeting 2-h postprandial blood glucose <7.5 mmol/l) or the 2) basal strategy (BASAL) (NPH twice daily or insulin glargine once daily targeting fasting/premeal blood glucose <6.7 mmol/l). RESULTS—A total of 1,115 patients were randomly assigned (PRANDIAL n = 557; BASAL n = 558), and the mean patient participation after randomization was 963 days (range 1–1,687 days). The trial was stopped for lack of efficacy. Risks of first combined adjudicated primary cardiovascular events in the PRANDIAL (n = 174, 31.2%) and BASAL (n = 181, 32.4%) groups were similar (hazard ratio 0.98 [95% CI 0.8–1.21]). Mean A1C did not differ between the PRANDIAL and BASAL groups (7.7 ± 0.1 vs. 7.8 ± 0.1%; P = 0.4) during the study. The PRANDIAL group showed a lower daily mean postprandial blood glucose (7.8 vs. 8.6 mmol/l; P < 0.01) and 2-h postprandial blood glucose excursion (0.1 vs. 1.3 mmol/l; P < 0.001) versus the BASAL group. The BASAL group showed lower mean fasting blood glucose (7.0 vs. 8.1 mmol/l; P < 0.001) and similar daily fasting/premeal blood glucose (7.7 vs. 7.3 mmol/l; P = 0.233) versus the PRANDIAL group. CONCLUSIONS—Treating diabetic survivors of AMI with prandial versus basal strategies achieved differences in fasting blood glucose, less-than-expected differences in postprandial blood glucose, similar levels of A1C, and no difference in risk for future cardiovascular event rates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated postchallenge (2-h oral glucose tolerance test) glucose values have been associated with increased cardiovascular risk independent of fasting plasma glucose in some epidemiologic studies, whereas intervention trials have not shown postprandial glucose to be a cardiovascular risk factor independent of A1C.”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [73]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most of the large outcome trials conducted so far have been mostly based on preprandial glucose and A1C targets, with limited evidence of a long-term benefit of targeting PPG alone (49,50).”
From Targets for Glycemic Control (2018) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, manipulating prandial glucose levels failed to impact clinical outcome, and therefore, this remains an unresolved area.142,143”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [143]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, a randomized controlled trial in patients with known CVD found no CVD benefit of insulin treatment plans targeting postprandial glucose compared with those targeting preprandial glucose (73).”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [73]
The cited source says what the claim attributes to it.
In the citing paper
“Elevated postchallenge (2-h oral glucose tolerance test) glucose values have been associated with increased cardiovascular risk independent of fasting plasma glucose in some epidemiologic studies, whereas intervention trials have not shown postprandial glucose to be a cardiovascular risk factor independent of A1C.”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [73]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 2×
“The Action to Control Cardiovascular Risk in Diabetes Study Group (ACCORD) trial (21) demonstrated increased mortality with intensive glycemic goals (A1C of 6.4%), the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial (22) showed similar cardiovascular outcomes wi…”
InfluentialDormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · cited 1×
“A similar separation in glycemic control was noted in the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) study (18), in which the primary composite cardiovascular end point failed to reach significance between therapies, but the secondary composite end point did reach significance.”
ResultStamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Diabetes and Atherosclerosis: Epidemiology, Pathophysiology, and Management
Beckman, J. A., Creager, M. A., & Libby, P. (2002) · JAMA · doi:10.1001/jama.287.19.2570 · Cited by 2,724
Cited by
Items 201–300 of 350
Scheen, A. J. (2010) · PubMed · Cited by 12
Cammarota, S., Falconio, L. M., Bruzzese, D., Catapano, A. L., Casula, M., Citarella, A., de Luca, L., Flacco, M. E., Manzoli, L., Masulli, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079762 · Cited by 11
“Conversely, the HEART2D trial [26] did not show any beneficial effect of specifically treating postprandial hyperglycemia in relation to the risk of cardiovascular events in diabetic patients.”
BackgroundWhat Options Are Available When Considering Starting Insulin: Premix or Basal?
Lavernia, F. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0248 · Cited by 10
“26 It is interesting that the findings revealed only modest differences in fasting and postprandial blood glucose levels between the two insulin regimens, with comparable A1C levels.”
Blood Glucose Control and Coronary Heart Disease
Bianchi, C., Penno, G., Miccoli, R., & Prato, S. D. (2010) · Herz · doi:10.1007/s00059-010-3340-4 · Cited by 9
“The Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus (HEART2D) [ 87 ] study recruited 1,115 T2DM patients within 21 days after an acute myocardial infarction and compared the effects on CV events of prandial insulin therapy strategy (th…”
MethodInfluentialCurrent insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes
Esposito, K., & Giugliano, D. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.648181 · Cited by 9
“The study trial ended prematurely due to futility [52].”
BackgroundStrategies for implementing effective mealtime insulin therapy in type 2 diabetes
Peyrot, M. F., Bailey, T. S., Childs, B. P., & Reach, G. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1440200 · Cited by 10
Paredes, S., Matta-Coelho, C., Monteiro, A. M., Brás, A., Marques, O., Alves, M., & Ribeiro, L. V. P. T. (2016) · HORMONES · doi:10.14310/horm.2002.1671 · Cited by 10
Yacoub, T. G. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1389601 · Cited by 7
“with T2D to either prandial or basal insulin, did not find any difference in risk of future CV events by treatment [59].”
BackgroundEASD, E. (2013) · Kardiologia Polska · doi:10.5603/kp.2013.0289 · Cited by 13
Sakharova, O. V., Lleva, R. R., Dziura, J. D., Spollett, G. R., Howell, S. K., Beisswenger, P. J., & Inzucchi, S. E. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.03.027 · Cited by 8
“, 1996), actual clinical trial data on the effect of controlling post-prandial hyperglycemia on cardiovascular morbidity have been conflicting (Davies, Storms, Shutler, Bianchi-Biscay, & Gomis, 2005; Raz et al., 2009; Riddle, Rosenstock, & Gerich, 2003; Rosenstock et al., 2005; Siegelaar, Kerr, Jacober, & Devries, 201…”
BackgroundCardiovascular Importance of Hyperglycemia and Hypoglycemia
Tkáč, I. (2013) · Diabetes Care · doi:10.2337/dcs13-2044 · Cited by 9
“The groups did not show any difference with respect to these individual outcomes or combinations of outcomes (18).”
BackgroundCounterpoint: Postprandial Glucose Levels Are Not a Clinically Important Treatment Target
Davidson, M. B. (2010) · Diabetes Care · doi:10.2337/dc10-0712 · Cited by 8
“On the other hand, documented significant lowering of postprandial glucose levels in the recent Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) study by premeal lispro insulin in diabetic patients with a recent acute myocardi…”
BackgroundKrajnc, M., Balon, B. P., & Krajnc, I. (2019) · Journal of International Medical Research · doi:10.1177/0300060518814080 · Cited by 9
“which involved the treatment of diabetic survivors of acute myocardial infarction with prandial versus basal strategies, the data showed differences in fasting blood glucose levels, smaller-than-expected differences in postprandial blood glucose levels, similar levels of HbA1C, and no difference in the risk of future…”
BackgroundParámetros de control glucémico: nuevas perspectivas en la evaluación del diabético
González-Clemente, J. M., & Llauradó, G. (2010) · Medicina Clínica · doi:10.1016/s0025-7753(10)70028-2 · Cited by 12
Management of Type 2 Diabetes Mellitus
Dungan, K. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00048-2 · Cited by 10
Raz, I. (2010) · Cardiology · doi:10.1159/000314330 · Cited by 7
Self-citationAmpudia‐Blasco, F. J., & Ceriello, A. (2010) · Medicina Clínica · doi:10.1016/s0025-7753(10)70031-2 · Cited by 7
Does Choice of Antidiabetes Therapy Influence Macrovascular Outcomes?
ZARICH, S. W. (2010) · Current Diabetes Reports · doi:10.1007/s11892-009-0083-9 · Cited by 6
“The HEART2D trial [ 57 ] randomized 1,115 T2DM subjects to a strategy of prandial versus basal insulin after acute myocardialinfarction.Thetrial was halted forstatistical futility when interim analysis showed no difference in CV event rates between the prandial and basal arms.”
BackgroundMethodInfluentialAcute coronary syndrome in diabetes mellitus: features of pathogenesis, course and therapy
Kokozheva, M. A., Марданов, Б. У., & Мамедов, М. Н. (2021) · Russian Journal of Preventive Medicine · doi:10.17116/profmed20212402189 · Cited by 6
Are Analogue Insulins Superior to Human Insulin in Clinical Practice?
Freeman, J. S. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0104-8 · Cited by 6
“Explanations from the authors for this finding included the advanced state of cardiovascular disease in the patients studied and that the difference in glycemic control between the two groups was more modest than anticipated, and overall glycemic goals were not achieved [ 22 ].”
BackgroundKohnert (2011) · Journal of Endocrinology and Metabolism · doi:10.4021/jem21w · Cited by 18
2. Glycaemic control assessment and targets in type 2 diabetes
Colagiuri, S., & Ceriello, A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112146 · Cited by 9
Cardiovascular Outcomes Trials in Type 2 Diabetes Mellitus
Kapoor, K., George, P., & Miller, M. J. (2016) · Cardiology · doi:10.1159/000446471 · Cited by 5
Hyperglycemia and Diabetes in Myocardial Infarction
Hernández, M. A. L. (2013) · InTech eBooks · doi:10.5772/48091 · Cited by 7
Raz, I., Cefalu, W. T., ILKOVA, H. M., & Prato, S. D. (2016) · Diabetes Care · doi:10.2337/dcs15-3030 · Cited by 5
Self-citationÉchec des antidiabétiques oraux à doses maximales tolérées : Quels traitements injectables?
Monnier, L., & Colette, C. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30030-x · Cited by 6
Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes
Cahn, A., Cernea, S., & Raz, I. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9351-6 · Cited by 5
Self-citationGlycemic Key Metrics and the Risk of Diabetes-Associated Complications
Kohnert, K., Heinke, P., Zander, E., Vogt, L., & Salzsieder, E. (2016) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.1515/rjdnmd-2016-0047 · Cited by 5
“The concept of treating pathologically elevated PPG to prevent cardiovascular complications was supported by a post-hoc analysis of the Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) study [13].”
MethodCardiovascular Outcomes Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes
Gerstein, H. C., & Shah, R. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.003 · Cited by 6
Insulin as an Early Treatment for Type 2 Diabetes
Prato, S. D., Bianchi, C., Dardano, A., & Miccoli, R. (2013) · Diabetes Care · doi:10.2337/dcs13-2019 · Cited by 7
“A more direct comparison may be made between ORIGIN and the Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients WithType 2DiabetesMellitus (HEART2D) (27) study.”
BackgroundRecent cardiovascular safety trials with antidiabetic drugs: time to change the guidelines!
Fisher, M. (2015) · Practical Diabetes · doi:10.1002/pdi.1980 · Cited by 4
Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms
BAJAJ, H. S., & Zinman, B. (2018) · Physiology · doi:10.1152/physiol.00004.2018 · Cited by 7
“Despite some pre-clinical and observational literature documenting the association of cardiovascular surrogate markers and outcomes to PPG (21, 29, 37, 77), none of the randomized trials with PPG-targeted approaches have been successful at reducing cardiovascular outcomes to date (58, 59, 88).”
BackgroundThe importance of randomization in clinical research
Sundaram, V., Selvaganesan, P., Deo, S. V., & Karnib, M. (2022) · Indian Journal of Thoracic and Cardiovascular Surgery · doi:10.1007/s12055-022-01401-7 · Cited by 7
Esposito, K., Maiorino, M. I., Bellastella, G., Chiodini, P., & Giugliano, D. (2011) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2010.0134 · Cited by 4
Naruse, R., Takebayashi, K., Morita, K., Aso, Y., & Inukai, T. (2011) · Endocrine Journal · doi:10.1507/endocrj.k11e-114 · Cited by 4
Ohara, M., Watanabe, K., Suzuki, T., Sekimizu, K.-I., Motoyama, M., Ishii, K., Sawai, K., Nakano, H., Oba, K., & Mizuno, K. (2013) · Journal of Nippon Medical School · doi:10.1272/jnms.80.200 · Cited by 4
Anggriani, Y., Purwanggana, A., & Restinia, M. (2017) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2017.v10i5.17136 · Cited by 5
Xing, Y., Wu, M., Liu, H., Li, P., Pang, G., Zhao, H., & Wen, T. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01269-0 · Cited by 4
Dysglycaemia, cardiovascular outcome and treatment. Is the jury still out?
Bartnik, M., & Cosentino, F. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp168 · Cited by 7
Son, J. W., Lee, I., Woo, J., Baik, S. H., Jang, H. C., Lee, K. W., Soo, B., Sung, Y., Park, T. S., Yoo, S.-J., et al. (2015) · Endocrine Journal · doi:10.1507/endocrj.ej15-0325 · Cited by 4
What are the best options for controlling prandial glycemia?
Clement, S. C. (2009) · Current Diabetes Reports · doi:10.1007/s11892-009-0056-z · Cited by 4
Dapagliflozin combination therapy in type 2 diabetes mellitus
Yacoub, T. G. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2016.1111119 · Cited by 6
“[14–16] In the HEART2D trial,[17] which was designed to compare the effects of prandial versus fasting glycemic control on CVoutcomes in patients with T2DM and a recent acute myocardial infarction, treatment of patients with postprandial insulin did not decrease CV event rates compared with those treated with once- or…”
MethodThe HEART2D trial—new questions beyond answers
Monnier, L., & Colette, C. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.98 · Cited by 4
Management of postprandial glucose: Recommended targets and treatment with biphasic insulin
Liebl, A. (2016) · Primary care diabetes · doi:10.1016/j.pcd.2016.06.002 · Cited by 5
Oxidative stress and glucose metabolism—is there a need to revisit effects of insulin treatment?
Humpert, P. M. (2010) · Diabetologia · doi:10.1007/s00125-009-1652-9 · Cited by 4
“The reported data could be of great importance, since previous clinical endpoint studies havefocused onthe indirect metabolic effects of insulin therapy geared primarily to achieving pre-defined HbA1c levels and reducing postprandial glucose excursions [ 9 , 11].”
BackgroundResultPostprandial Blood Glucose-Focused Dietary Approaches and Their Limitations
Jiménez, M. D. C. F.-F. (2025) · Journal of Nutrition · doi:10.1016/j.tjnut.2025.09.037 · Cited by 3
Villar‐Taibo, R., Sanz-Pastor, A. G., Fernández-Rubio, E., Galindo, D. E. B., Simó-Servat, A., & Ampudia‐Blasco, F. J. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0524 · Cited by 4
Rapid-acting insulin glulisine: an update on clinical experience
DAILEY, G. E. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.40 · Cited by 4
Nasrallah, M., Khalil, C. A., & Refaat, M. M. (2017) · BioMed Research International · doi:10.1155/2017/9257930 · Cited by 5
“The Hyperglycemia and Its Effect after Acute Myocardial Infarction onCardiovascularOutcomes in Patients with Type 2 DiabetesMellitus (HEART2D) study was designed to target postprandial glucose with short-acting insulin as compared to fasting glucose with basal insulin in patients with acute MI occurring within 3 weeks…”
MethodKakorin, S. V., Iskandaryan, R. A., & Mkrtumyan, A. M. (2016) · Diabetes Mellitus · doi:10.14341/dm2003422-27 · Cited by 3
La variabilité glycémique : un facteur de risque singulier à conjuguer au pluriel
Monnier, L., Colette, C., Bonnet, F., & Owens, D. R. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.11.003 · Cited by 3
Bladbjerg, E., Henriksen, J. E., Akram, S., & Gram, J. (2011) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2011.00711.x · Cited by 3
[Hypoglycemic therapy in heart disease patients with type 2 diabetes mellitus].
Cosmi, F., & Cosmi, D. (2010) · PubMed · Cited by 3
Rees, T. M., Curtis, B. H., Gaskins, K. A., Sierra‐Johnson, J., Jiang, H. H., Liu, R., & Holcombe, J. H. (2013) · Endocrine Practice · doi:10.4158/ep13301.or · Cited by 3
Objectifs du contrôle de la glycémie
Imran, S. A., RABASA-LHORET, R. P. R., & Ross, S. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.036 · Cited by 4
Quo vadisnateglinide? Ten-year perspective
Grunberger, G. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.600305 · Cited by 3
“, HEART2D) yielded inconclusive results [61].”
Bladbjerg, E., Henriksen, J. E., Akram, S., & Gram, J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01547.x · Cited by 4
“The beneficial effect of reducing postprandial glucose on clinical endpoints was recently questioned in a randomised controlled trial (HEART2D) showing that the risk of future CVD is similar, when either mealtime insulin or bedtime insulin is used as secondary prevention in type 2 diabetes patients experiencing a rece…”
BackgroundAntidiabetic Therapy in End‐Stage Renal Disease
Boyle, S. M., Simon, B. F., & KOBRIN, S. M. (2015) · Seminars in Dialysis · doi:10.1111/sdi.12368 · Cited by 4
“also no superior approach—basal or meal-time— with respect to reduction in HBA1C or other clinical outcomes (59).”
BackgroundWade, M. T., & Rindone, J. P. (2011) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31820159aa · Cited by 3
“was compared with lispro insulin given before meals in 1115 patients with T2DM and coronary artery disease.(25) The results show no difference in cardiovascular events between groups with a nonsignificant trend toward higher mortality in the lispro insulin group.”
MethodDiabetes mellitus and cardiovascular diseases
Pelikánová, T. (2011) · Cor et Vasa · doi:10.33678/cor.2011.054 · Cited by 3
Oh, T. J. (2016) · Journal of Korean Diabetes · doi:10.4093/jkd.2016.17.4.233 · Cited by 3
Restricted Time Win Ratio: From Estimands to Estimation
Wang, T., Li, Y., & Qu, Y. (2024) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2024.2332675 · Cited by 6
“In this section, we applied the multiple imputation method described in Section 2 to estimate the RTWR using data from the HEART2D study (Raz et al. 2009).”
Hosseinsabet, A., Etesamifard, N., Shafiee, A., Jalali, A., Heidari, A., Heidari, N., Ariannejad, H., & Aghajani, H. (2025) · Health Science Reports · doi:10.1002/hsr2.71369 · Cited by 2
Curtis, B. H., Rees, T. M., Gaskins, K. A., Sierra‐Johnson, J., Liu, R., Jiang, H. H., & Holcombe, J. H. (2013) · Aging Clinical and Experimental Research · doi:10.1007/s40520-013-0125-7 · Cited by 2
“This study consisted of an initial 18-month treatment period followed by an extended follow-up phase of up to 5 1/2 years, for a total potential duration of treatment of up to 7 years [12].”
BackgroundMethodInfluentialFüchtenbusch, M. (2014) · Der Diabetologe · doi:10.1007/s11428-013-1147-7 · Cited by 2
Le seuil du « p » statistique à 0,05 est-il fiable ou non ? Telle est la question
Monnier, L., Colette, C., & Halimi, S. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30177-9 · Cited by 2
Medikamentös induzierte Hypoglykämie bei Typ-2-Diabetes-Patienten
Schneider, C. A. (2011) · Der Diabetologe · doi:10.1007/s11428-011-0709-9 · Cited by 2
Bolli, G. B., Deeb, L. C., Garg, S. K., Leahy, J. L., Mazze, R. S., Owens, D. R., Riddle, M. C., Southerland, P., & Strock, E. S. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0179 · Cited by 2
Type 2 diabetes: the evolution of a disease
Lebovitz, H. E. (2012) · The British Journal of Diabetes · doi:10.1177/1474651412470289 · Cited by 3
Raz, I. (2009) · Diabetes Care · doi:10.2337/dc09-s300 · Cited by 2
“On the other hand, however, the results of several trials—the Action in Diabetes and Vascular Disease Trial (ADVANCE) (4), the Action to Control Cardiovascular Risk in Diabetes Study (ACCORD) (5), the VA Diabetes Trial (VADT) (6), and Heart 2D study (7)— have cast doubt on the benefits of tight glucose control in olde…”
ResultSelf-citationHyperglycemia, hypoglycemia and glycemic variability in the elderly: a fatal triad?
Monami, M., & Aleffi, S. (2016) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2015.726 · Cited by 2
(2010) · Elsevier eBooks · doi:10.1016/b978-2-294-70868-8.50004-9 · Cited by 2
Management of Diabetes Mellitus with Insulin Lispro
Tanaka, M., & Itoh, H. (2011) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s1155 · Cited by 2
Glycemic Variability and Its Clinical Implications
Verma, N. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812019-4.00021-0 · Cited by 4
Tinahones, F. J., Molina‐Vega, M., Parra-Barona, J., Roux, J. A. F., & Gómez‐Huelgas, R. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0452-8 · Cited by 2
Wang, J., Lee, I., Lee, W., Lin, S., Lee, W.-L., Liang, K., & Sheu, W. H. (2021) · Journal of Investigative Medicine · doi:10.1136/jim-2020-001646 · Cited by 3
Lalic, N. M., & Landers, B. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0165 · Cited by 2
Rosiglitazone and Cardiovascular Outcomes: Is There a Clear Answer?
Gerstein, H. C. (2013) · Circulation · doi:10.1161/circulationaha.113.004652 · Cited by 2
WITHDRAWN: Targets for Glycemic Control
Imran, S. A., RABASA-LHORET, R. P. R., & Ross, S. A. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.04.008 · Cited by 4
RetractedVersorgungsLeitlinie, N. (2011) · Cited by 2
Postprandial Hyperglycemia and Cardiovascular Disease
Yoon, J. S. (2012) · Journal of Korean Diabetes · doi:10.4093/jkd.2012.13.1.18 · Cited by 1
How to interpret results of the HEART2D trial?
Tkáč, I., Miličević, Z., & Jermendy, G. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(09)70010-5 · Cited by 1
Self-citationDzhavakhishvili, T. S., Romantsova, T. I., & Роик, О. В. (2013) · Obesity and metabolism · doi:10.14341/2071-8713-5067 · Cited by 1
Pharmacothérapie du diabète de type 2
Harper, W., CLEMENT, M. A., Goldenberg, R., Hanna, A., Main, A., Retnakaran, R. R., Sherifali, D., Woo, V. C., & Yale, J. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.006 · Cited by 1
Postprandial or Fasting Hyperglycemia: Time to Move On?
DeVries, J. H. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0158 · Cited by 1
Meng, X., Gong, C., Cao, B., & Peng, X. (2015) · International Journal of Pediatric Endocrinology · doi:10.1186/1687-9856-2015-s1-p22 · Cited by 2
Antihyperglycemic drugs and cardiovascular outcomes in type 2 diabetes
Ganda, O. P. (2016) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.83.s1.03 · Cited by 1
Kardiovaskuläre Effekte der Insulintherapie
Pfohl, M. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0088-3 · Cited by 1
“Auch in der VADT zeigte sich erst in der Nachbeobachtungsphase nach einem medianen Follow-up von 9,8 Jahren eine Reduktion kardiovaskulärer Ereignisse mit einer HR („hazard ratio“) von 0,83 (95 %-KI: 0,70–0,99) trotz der zwischenzeitlichen Annäherung der Blutzuckereinstellung in den beiden untersuchten Patientengruppe…”
BackgroundInfluentialTherapie postprandialer Blutzuckerspitzen – sinnvoll oder nur Blutzuckerkosmetik?
Forst, T. M. (2017) · Der Diabetologe · doi:10.1007/s11428-017-0259-x · Cited by 1
“InderHEART2D-Studie (HEART2D: „hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with type 2 diabetes mellitus“) wurde der Effekt einer Therapie mit einem Basalinsulin mit dem einer prandialen Insulinsubstitution im Hinblick auf kardiovaskuläre Endpunkte verglichen […”
BackgroundKrasilnikova, E. I., Blagosklonnaya, Y. V., Баранова, Е. И., Grineva, E. N., Bystrova, A. A., Ryumina, I. A., Volkova, A. R., & Каронова, Т. Л. (2009) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2009-15-6-640-647 · Cited by 2
Sun, X., Bao, B. N., Gao, X., Yan, D., & Zhou, Y. (2015) · Europe PMC (PubMed Central) · Cited by 1
Importance of the postprandial glycemic control in the patient with Type 2 Diabetes Mellitus
Benítez, A., Benítez, G., Barriocanal, L. A., Bueno, E., Caballero, A., Cañete, F., Jiménez, J., Logwin, S., Menoni, C., Palacios, M., et al. (2016) · Anales de la Facultad de Ciencias Médicas (Asunción) · doi:10.18004/anales/2015.048(01)83-100 · Cited by 4
“Glucagon-like peptide-1 [7-36]: a physiological incre tin in man.”
BackgroundAnti-diabetic Drugs Utilization in Type 2 Diabetic Patients in AL-Nasiriya Governorate / Iraq
Motar, B. A. (2017) · American Journal of Internal Medicine · doi:10.11648/j.ajim.20170506.12 · Cited by 1
“Diabetes mellitus type 2 is a chronic disease characterized by coexisting insulin deficiency and insulin resistance, with the resultant hyperglycemia leading to micro and macro vascular complications [5, 6].”
BackgroundDiabetestherapie bei nichtalkoholischer Fettlebererkrankung und Leberzirrhose
Bojunga, J. (2020) · Die Gastroenterologie · doi:10.1007/s11377-020-00417-y · Cited by 1
Setting glycaemic targets in patients with type 2 diabetes. Where to now?
Distiller, L. A. (2009) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2009.10872208 · Cited by 1
Argente, M. (2020) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya) · doi:10.6035/14112.2020.579334 · Cited by 1
Continuous monitoring blood glucose level in clinical practice and new methods for its analysis
Dreval', A. V., Dreval, O., & Starostina, E. G. (2013) · Problems of Endocrinology · doi:10.14341/probl201359441-49 · Cited by 3
Prise en charge du diabétique après infarctus du myocarde
Halbron, M., Jacqueminet, S., & Grimaldi, A. (2010) · Elsevier eBooks · doi:10.1016/b978-2-294-70868-8.50020-7
Tushuizen, M. E. (2012) · Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam)
Giménez, M. (2012) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · Cited by 1
Metadata
- Authors
- Raz, I., Wilson, P. W. F., Strojek, K., Kowalska, I., Bozikov, V., Gitt, A. K., Jermendy, G., Campaigne, B. N., Kerr, L., Milicevic, Z., & Jacober, S. J.
- Affiliations
- Hadassah Medical Center (IL)
- Emory University (US)
- Medical University of Silesia (PL)
- Medical University of Białystok (PL)
- Endocrinology, Diabetes and Metabolic Diseases, University Hospital Dubrava, Zagreb, Croatia
- Cardiology, Herzzentrum Ludwigshafen, Ludwigshafen, Germany
- Medical Department, Bajcsy-Zsilinszky Teaching Hospital, Budapest, Hungary
- Eli Lilly (United States) (US)
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-03-01
- Volume
- 32
- Issue
- 3
- Pages
- 381-386
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2646013
- OpenAlex
- W2172111876
- Cited by
- 351
- References
- 26
- Citations by year
- 2025: 5 · 2024: 9 · 2023: 2 · 2022: 5 · 2021: 12 · 2020: 13 · 2019: 18 · 2018: 20 · 2017: 22 · 2016: 28 · 2015: 36 · 2014: 25 · 2013: 35 · 2012: 24
- FWCI
- 29.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- type 2 diabetes, acute myocardial infarction, insulin lispro, basal insulin, postprandial blood glucose, glycemic excursions, cardiovascular outcomes, HbA1c, lack of efficacy
- MeSH terms
- Insulin Glargine, Adult, Aged, Body Weight, Cardiovascular System, Diabetes Mellitus, Type 2, Drug Administration Schedule, Fasting, Female, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Risk Factors, Treatment Outcome, Postprandial Period, Insulin, Long-Acting, Insulin Lispro
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.